[{"id":"quest-exacerbations","name":"Annualized severe asthma exacerbation rate","type":"PRIMARY","unit":"events/year","results":[{"notes":"47.7% reduction vs placebo","value":0.46,"arm_id":"dupixent-300-quest","arm_name":"Dupilumab 300mg Q2W"},{"notes":"Rate ratio 0.52 (0.41-0.66), p<0.001","value":0.87,"arm_id":"placebo-quest","arm_name":"Placebo"}],"timepoint":"Week 52","description":"Annualized rate of severe asthma exacerbations (defined as worsening requiring systemic corticosteroids for ≥3 days, ER visit, or hospitalization). Lower is better."}]

QUEST met primary endpoint: 47.7% reduction in severe exacerbation rate with Dupilumab 300mg Q2W vs placebo (RR 0.52, p<0.001). FEV1 improved +0.13L vs placebo at Week 12 (p<0.001). Benefit seen across eosinophil subgroups.

QUEST (n=1902, 52 weeks): Injection site reactions 18% vs 6%. Transient eosinophilia 5% vs 1% (resolved on treatment). No meaningful safety differences otherwise.

QUEST established Dupixent in asthma. The 48% exacerbation reduction is strong. Key differentiator vs IL-5 biologics: Dupixent also improves FEV1 (lung function) which IL-5s generally do not. This is why Dupixent became the #1 asthma biologic.

Type 2 inflammation (IL-4/IL-13) drives eosinophilic asthma. Dupilumab blocks both cytokines via IL-4Rα.